The Vulnerable Phase of Heart Failure

Am J Ther. 2018 Jul/Aug;25(4):e456-e464. doi: 10.1097/MJT.0000000000000794.
No abstract available

MeSH terms

  • Acute Disease / mortality
  • Acute Disease / therapy
  • Biomarkers / blood
  • Cardiac Resynchronization Therapy / methods
  • Cardiac Resynchronization Therapy Devices
  • Cardiovascular Agents / therapeutic use*
  • Defibrillators, Implantable
  • Heart / drug effects
  • Heart / physiopathology*
  • Heart Failure / blood
  • Heart Failure / mortality
  • Heart Failure / physiopathology*
  • Heart Failure / therapy*
  • Hospital Mortality
  • Hospitalization / statistics & numerical data
  • Humans
  • Prognosis
  • Risk Assessment
  • Stroke Volume / drug effects
  • Time Factors

Substances

  • Biomarkers
  • Cardiovascular Agents